MedElevator
Войти в исследования Future oncology (London, England) · 2025
A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Leger Paul, Frencher Stanley, Nauseef Jones T, Jones Brian, Bilen Mehmet A, Brown Alan, Ullah Aminha, McDevitt Shane, Tsao Che-Kai
Аннотация
AIMS: This study aimed to partner with patients, advocates, and physicians to better understand the barriers that exist for Black and African Americans to enroll in prostate cancer (PCa) clinical trials.
PATIENTS & METHODS: Through moderated discussions with patients, advocates, and physicians, we identified potential opportunities to increase the enrollment of underrepresented patients in PCa clinical trials.
RESULTS: We identified key barriers to Black and African American enrollment in PCa clinical trials that were shared by all groups but also identified group-specific barriers. We developed recommendations based on key themes that have the potential to increase the enrollment of Black and African Americans in PCa clinical trials.
CONCLUSIONS: While racial diversity in PCa clinical trials remains an unsolved problem, there are significant opportunities to better address this unmet need. Through a multi-perspective approach to identify key barriers that limit Black and African American enrollment in PCa clinical trials, we developed recommendations for both sponsors and clinical trial sites to increase diverse patient enrollment in PCa clinical trials, with a focus on employing practical strategies.
PATIENTS & METHODS: Through moderated discussions with patients, advocates, and physicians, we identified potential opportunities to increase the enrollment of underrepresented patients in PCa clinical trials.
RESULTS: We identified key barriers to Black and African American enrollment in PCa clinical trials that were shared by all groups but also identified group-specific barriers. We developed recommendations based on key themes that have the potential to increase the enrollment of Black and African Americans in PCa clinical trials.
CONCLUSIONS: While racial diversity in PCa clinical trials remains an unsolved problem, there are significant opportunities to better address this unmet need. Through a multi-perspective approach to identify key barriers that limit Black and African American enrollment in PCa clinical trials, we developed recommendations for both sponsors and clinical trial sites to increase diverse patient enrollment in PCa clinical trials, with a focus on employing practical strategies.